Company Overview and News

 
Covanta - New Senior Notes Examined

2018-10-08 seekingalpha
Covanta Holding Corporation (CVA) is taking active steps to restructure its corporate debt. These movements will allow it to continue its growth with greater financial stability.
CVA

 
CVA / Covanta Holding Corp. 424B2 (Prospectus)

2018-10-05 sec.gov
424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-220460 CALCULATION OF REGISTRATION FEE
CVA

1
CVA / Covanta Holding Corp. FORM 8-K (Current Report)

2018-10-04 sec.gov - 1
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CVA

42
Alternative Energy Stock Outlook: Short-Term Prospects Bright

2018-10-04 zacks - 1
Technological advancements in recent times have brought down the cost of generating electricity from alternative energy sources and storing the same. In this backdrop, the outlook for the U.S. alternative energy stocks remains favorable as utilities and corporations are increasingly shifting to renewables. However, policy uncertainties in the nation under Trump’s administration have been an overhang on the stocks’ prospects in the near term.
GEVO DM STOHF NEP CVA STO

 
CVA / Covanta Holding Corp. FORM 8-K (Current Report)

2018-10-03 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CVA

 
CVA / Covanta Holding Corp. FWP

2018-10-03 sec.gov
FWP Issuer Free Writing Prospectus Filed by: Covanta Holding Corporation Pursuant to Rule 433 under the Securities Act of 1933 Registration Statement No
CVA

 
CVA / Covanta Holding Corp. 424B5 (Prospectus)

2018-10-03 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-220460 This preliminary prospectus supplement relates to an effective registration statement but it is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell
CVA

 
CVA / Covanta Holding Corp. 8-K (Current Report)

2018-10-03 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CVA

 
CVA / Covanta Holding Corp. 8-K (Current Report)

2018-09-25 sec.gov
Document UNITED STATES
CVA

1
CVA / Covanta Holding Corp. 8-K (Current Report)

2018-08-30 sec.gov - 1
Document UNITED STATES
CVA

 
CVA / Covanta Holding Corp. 8-K (Current Report)

2018-08-21 sec.gov
Document UNITED STATES
CVA

6
9 Great Income Investments You’ve Never Heard Of

2018-08-08 investorplace
Like income? If you’re reading this, then you likely do. And odds are good you’re more than a little familiar with the usual suspects … utilities stocks like Southern Co (NYSE:SO), or diversified healthcare giant Pfizer (NYSE:PFE). The former is recession proof, while the latter always seems able to find a market by constantly reinventing its drug portfolio, making them a couple of the best income-producing assets the market has to offer.
SOJA SO NLSN OAK HTGX HTGY IRM HTGZ HTGC PFE CVA OUT CWB

9
Ormat Technologies (ORA) Q2 Earnings Miss, Revenues Top

2018-08-08 zacks
Ormat Technologies Inc.’s (ORA - Free Report) second-quarter 2018 adjusted earnings per share (EPS) came in at 32 cents, missing the Zacks Consensus Estimate of 48 cents by 33.3%. Earnings also declined 44.8% from the prior-year quarter figure. Barring one-time items, the company incurred a GAAP loss of a penny per share, in the quarter, against earnings of 17 cents in the year-ago quarter. Revenues In the quarter under review, Ormat Technologies generated revenues $178.
APC ELY ICFI GPOR AEUA CVA ORA

 
Covanta Holding Corporation (CVA) CEO Steve Jones on Q2 2018 Results - Earnings Call Transcript

2018-07-27 seekingalpha
Good morning, everyone and welcome to the Covanta Holding Corporation’s Second Quarter 2018 Financial Results Conference Call and Webcast. An archived webcast will be available 2 hours after the end of the conference call and can be accessed through the Investor Relations section of the Covanta website at www.covanta.com. The transcript will also be archived on the company’s website. At this time for opening remarks and introductions, I would like to turn the call over to Dan Mannes, Covanta’s Vice President of Investor Relations.
CVA

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CVA / Covanta Holding Corp. on message board site Silicon Investor.

Cavitation Technologies, Inc. (CTI); (OTC: CVAT) Cavitation Technologies, Inc. (CTI); (OTC: CVAT) Cavitation Technologies, Inc. (CTI); (OTC: CVAT) CVAS-an interesting california-based biotech company here CVAS-an interesting california-based biotech company here CVAS-an interesting california-based biotech company here
Consolidated Venturex Holdings Ltd Consolidated Venturex Holdings Ltd Consolidated Venturex Holdings Ltd CVAN -Crown Vantage paper company. CVAN -Crown Vantage paper company. CVAN -Crown Vantage paper company.
Corvas International(CVAS) Corvas International(CVAS) Corvas International(CVAS)
CUSIP: 22282E102